Open Orphan Subsidiary Signs Deal With Global Pharmaceutical Company
Contract research company Open Orphan said its subsidiary hVivo had signed an agreement with a major pharmaceutical customer to manufacture a virus for use in human challenge studies.
The Anonymous Client is a top-five global company, Open Orphan said. The value of the deal was not disclosed, but Open Orphan said the contract was “substantial”.
Manufacturing has already started and work should be completed by the end of the third quarter.
Open Orphan said it was optimistic that a characterization study, which establishes the right dose of virus to cause safe and reliable infection in healthy volunteers, and a substantial human challenge study would follow completion of the manufacturing process. .
“This contract demonstrates our world-class capabilities across the entire challenge trial process, starting with virus manufacturing, through characterization study and challenge study execution. This contract illustrates our ability to leverage this to build deep and lasting relationships with our clients over long periods of time,” said Yamin Khan, Managing Director of Open Orphan.
“This contract is also another example of the company’s ability to secure repeat contracts from its existing base of Big Pharma customers, who have great confidence in our decades of experience in world-leading clinical trials. global level. With this experience coupled with our expanded offering following facility expansion, I look forward to providing additional clinical services support to the significantly expanded and growing infectious and respiratory disease market.
Open Orphan, a European rare and orphan drug advisory services platform, is the result of executive chairman Cathal Friel flipping his namesake pharmaceutical services business into Dublin-listed director of clinical drug trials Venn Life. Science.